Altogether our study demonstrates the potential of using chromosomal aberrations to guide preclinical development of targeted therapeutic approaches and adds to the mounting evidence that CHK1 might be an effective therapeutic target for the treatment of NB (13). This evidence concerns the gene CHEK1 and neuroblastoma.